Insider · CIK 0001631486
Magda Marquet
Files at ANAB (ANAPTYSBIO, INC), ARCT (Arcturus Therapeutics Holdings Inc.), IMMX (Immix Biopharma, Inc.), TRAX (First Tracks Biotherapeutics, Inc.). First filing Jan 16, 2026, latest Jan 16, 2026.
Magda Marquet files SEC Form 4 as director at ANAB (ANAPTYSBIO, INC), and also at ARCT (Arcturus Therapeutics Holdings Inc.), IMMX (Immix Biopharma, Inc.), TRAX (First Tracks Biotherapeutics, Inc.). Since Jan 16, 2026, Magda Marquet has reported 0 open-market buys worth $0 and 1 open-market sell worth $531k, the latest filed on Jan 16, 2026.
A track record needs three past buys with six months of prices behind them; Magda Marquet has 0, so none is measured yet.
The newest scored trade: sold $531k of ANAB on Jan 15, 2026, filed Jan 16, 2026, scored 53 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $531k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANAB: ANAPTYSBIO, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | ANAPTYSBIO, INC | $531k 11,000 shares | -53% | +274% from low-9% from high |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | TRAX First Tracks Biotherapeutics, Inc. | MOption exercise Common Stock | +6,030 | $0.00 | $0 | 15,960 | Jun 17, 2026 |
| Jun 15, 2026 | TRAX First Tracks Biotherapeutics, Inc. | MOption exercise Restricted Stock Unitderivative | -6,030 | $0.00 | $0 | 0 | Jun 17, 2026 |
| Jun 5, 2026 | ARCT Arcturus Therapeutics Holdings Inc. | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 15, 2026 |
| May 12, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Restricted Stock Unitderivative | +15,000 | $0.00 | $0 | 15,000 | May 14, 2026 |
| May 12, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +42,000 | $0.00 | $0 | 42,000 | May 14, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +784 | $0.00 | $0 | 784 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,000 | $0.00 | $0 | 11,000 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +9,200 | $0.00 | $0 | 9,200 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,600 | $0.00 | $0 | 10,600 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,510 | $0.00 | $0 | 16,510 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,510 | $0.00 | $0 | 16,510 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,500 | $0.00 | $0 | 5,500 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Restricted Stock Unitderivative | +6,030 | $0.00 | $0 | 6,030 | Apr 22, 2026 |
| Apr 20, 2026 | TRAX First Tracks Biotherapeutics, Inc. | AGrant or award Restricted Stock Unitderivative | +4,000 | $0.00 | $0 | 4,000 | Apr 22, 2026 |
| Jan 15, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +11,000 | $26.11 | $287k | 20,930 | Jan 16, 2026 |
| Jan 15, 2026 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock | -9,290 | $48.12 | $447k | 11,640 | Jan 16, 2026 |
| Jan 15, 2026 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock | -1,710 | $48.85 | $84k | 9,930 | Jan 16, 2026 |
| Jan 15, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Stock Option (right to buy)derivative | -11,000 | $0.00 | $0 | 0 | Jan 16, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | AGrant or award Stock Option (right to buy)derivative | +5,500 | $0.00 | $0 | 5,500 | Jan 8, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | AGrant or award Restricted Stock Unitderivative | +4,000 | $0.00 | $0 | 4,000 | Jan 8, 2026 |
| Jun 20, 2025 | IMMX Immix Biopharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 15, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +6,030 | $0.00 | $0 | 9,930 | Jun 17, 2025 |
| Jun 15, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -6,030 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 9, 2025 | ARCT Arcturus Therapeutics Holdings Inc. | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Stock Option (right to buy)derivative | +16,510 | $0.00 | $0 | 16,510 | Jan 7, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Restricted Stock Unitderivative | +6,030 | $0.00 | $0 | 6,030 | Jan 7, 2025 |
Questions about Magda Marquet
Answered from the filings on this page, as of the latest one.
Is Magda Marquet buying or selling?
In the last 12 months Magda Marquet reported 0 open-market buys worth $0 and 1 open-market sell worth $531k on SEC Form 4; the latest was sold $531k of ANAB on Jan 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Magda Marquet's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Magda Marquet has 0.
Where does Magda Marquet file Form 4?
Magda Marquet has filed Form 4 at ANAB (ANAPTYSBIO, INC); ARCT (Arcturus Therapeutics Holdings Inc.); IMMX (Immix Biopharma, Inc.); TRAX (First Tracks Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.